Blastomyces Dermatitidis Antigen (JWW)
510(k) K792680
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK792680 | Date17 Jan 1980 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- Full name
- Blastomyces Dermatitidis, Antigen
- 510(k) Number
- FDA Product Code
- JWW
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.3060
- Advisory Committee
- Microbiology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
This device is an Antigen, Cf, B. Dermatitidis, classified under the Microbiology category. It is designed for diagnostic use in identifying Blastomyces dermatitidis antigens, aiding in the detection of infections caused by this fungal pathogen.
The antigen test is supplied as a Class 2 diagnostic device under 21 CFR 866.3060, cleared via the Traditional 510(k) pathway (K792680). It is intended for in vitro use with serum, plasma, or body fluids, though urine specimens require a separate assay. No regulatory status beyond the stated FDA clearance is implied.
Other devices from Meridian Diagnostics, Inc.
Questions
AI-generated answers, 19 Sep 2026
What types of samples can this test detect *Blastomyces dermatitidis* antigens in, and are there any limitations?
This test is designed for in vitro use with serum, plasma, or body fluids to detect *Blastomyces dermatitidis* antigens. However, urine specimens require a separate assay, so it is not suitable for direct urine testing without additional processing.
Is this device intended for single-use or can it be reused?
The device is classified as a Class 2 diagnostic antigen test, which typically implies single-use for clinical diagnostic purposes. Reuse is not mentioned in the specifications, and reprocessing could compromise accuracy or sterility.
What regulatory pathway was used to clear this device, and what does that mean for its use?
This device was cleared via the Traditional 510(k) pathway (K792680) under 21 CFR 866.3060, meaning it was determined to be substantially equivalent to a legally marketed predicate device. This clearance ensures it meets FDA standards for safety and effectiveness as an in vitro diagnostic for detecting *Blastomyces dermatitidis* antigens.
What medical specialty is this device primarily associated with, and why?
This device falls under the Microbiology medical specialty category, as it is specifically designed for diagnostic use in identifying *Blastomyces dermatitidis* antigens. This classification aligns with its role in laboratory testing for fungal infections.